OncoSec Medical (ONCS) Shares Gap Up to $1.43

OncoSec Medical Inc (NASDAQ:ONCS) shares gapped up before the market opened on Tuesday . The stock had previously closed at $1.38, but opened at $1.43. OncoSec Medical shares last traded at $1.50, with a volume of 2686800 shares trading hands.

A number of research analysts have recently commented on the company. Piper Jaffray Companies raised their price target on OncoSec Medical to $5.00 and gave the company an “overweight” rating in a report on Tuesday, August 14th. HC Wainwright set a $4.00 price target on OncoSec Medical and gave the company a “buy” rating in a report on Friday, June 29th. Finally, Dawson James reissued a “buy” rating on shares of OncoSec Medical in a report on Monday, July 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. OncoSec Medical currently has an average rating of “Buy” and an average target price of $4.67.

The company has a market cap of $78.52 million, a price-to-earnings ratio of -1.43 and a beta of 2.90.

In related news, CFO Richard B. Slansky sold 84,984 shares of the firm’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $1.39, for a total transaction of $118,127.76. Following the completion of the transaction, the chief financial officer now owns 255,000 shares of the company’s stock, valued at $354,450. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Avtar S. Dhillon sold 37,575 shares of the firm’s stock in a transaction dated Thursday, July 5th. The shares were sold at an average price of $1.39, for a total value of $52,229.25. Following the transaction, the director now directly owns 181,002 shares of the company’s stock, valued at approximately $251,592.78. The disclosure for this sale can be found here. Insiders have sold 130,380 shares of company stock valued at $181,150 in the last ninety days. Company insiders own 5.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC bought a new position in OncoSec Medical during the second quarter valued at about $414,000. Millennium Management LLC boosted its stake in OncoSec Medical by 19.5% during the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock valued at $1,650,000 after buying an additional 194,739 shares in the last quarter. Nexthera Capital LP boosted its stake in OncoSec Medical by 26.6% during the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock valued at $3,608,000 after buying an additional 550,000 shares in the last quarter. DRW Securities LLC boosted its stake in OncoSec Medical by 157.1% during the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 110,000 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in OncoSec Medical by 1,303.5% during the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 221,916 shares in the last quarter. 26.15% of the stock is owned by institutional investors and hedge funds.

About OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Recommended Story: Stop Order Uses For Individual Investors

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply